Copy to clipboard 
ORTHOWORLD estimates Integra LifeSciences’ (IART) 2Q18 orthopaedic revenue at US $30.4MM, -0.6% vs. 2Q17, and 1H18 revenue of $55.2MM, -2.5% vs. 1H17.
Estimated segment sales and growth follow.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Recon Extremities | $11.9 | $11.3 | $0.5 | 4.5% |
| Trauma | $18.5 | $19.2 | -$0.7 | -3.5% |
| Total | $30.4 | $30.6 | -$0.2 | -0.6% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Recon Extremities | $21.5 | $20.7 | $0.8 | 3.9% |
| Trauma | $33.7 | $35.9 | -$2.2 | -6.2% |
| Total | $55.2 | $56.6 | -$1.4 | -2.5% |
ORTHOWORLD’s estimated revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $26.2 | $47.5 |
| Ex-U.S. | $4.3 | $7.7 |
IART has completed the expansion of its Orthopaedics and Tissue Technologies segment (which includes non-ortho product sales) and now, extremities orthopaedics is among four channels with fully-dedicated sales staff. Leadership indicated that, of ~30 reps added in the quarter, the majority were added for orthopaedics with the remainder added to outpatient wound, inpatient advanced wound care and surgical reconstruction.
The Integra XT Ankle Revision System launched after the quarter’s close, complementing the company’s total ankle range. It features bone sparing characteristics and streamlined instrumentation. The later-2018 launch of the Panta II ankle nail remains on track.
Ankle sales overall grew in mid-single-digits, with good performance called out for the Cadence device. Shoulders grew in double digits. Extremities Ortho growth is expected to begin seeing more meaningful increases in 2H18.
Sources: Integra LifeSciences; ORTHOWORLD Inc. estimates
ORTHOWORLD estimates Integra LifeSciences’ (IART) 2Q18 orthopaedic revenue at US $30.4MM, -0.6% vs. 2Q17, and 1H18 revenue of $55.2MM, -2.5% vs. 1H17.
Estimated segment sales and growth follow.
Q18
Q17
$ Change
% Change
Joint...
ORTHOWORLD estimates Integra LifeSciences’ (IART) 2Q18 orthopaedic revenue at US $30.4MM, -0.6% vs. 2Q17, and 1H18 revenue of $55.2MM, -2.5% vs. 1H17.
Estimated segment sales and growth follow.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Recon Extremities | $11.9 | $11.3 | $0.5 | 4.5% |
| Trauma | $18.5 | $19.2 | -$0.7 | -3.5% |
| Total | $30.4 | $30.6 | -$0.2 | -0.6% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Recon Extremities | $21.5 | $20.7 | $0.8 | 3.9% |
| Trauma | $33.7 | $35.9 | -$2.2 | -6.2% |
| Total | $55.2 | $56.6 | -$1.4 | -2.5% |
ORTHOWORLD’s estimated revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $26.2 | $47.5 |
| Ex-U.S. | $4.3 | $7.7 |
IART has completed the expansion of its Orthopaedics and Tissue Technologies segment (which includes non-ortho product sales) and now, extremities orthopaedics is among four channels with fully-dedicated sales staff. Leadership indicated that, of ~30 reps added in the quarter, the majority were added for orthopaedics with the remainder added to outpatient wound, inpatient advanced wound care and surgical reconstruction.
The Integra XT Ankle Revision System launched after the quarter’s close, complementing the company’s total ankle range. It features bone sparing characteristics and streamlined instrumentation. The later-2018 launch of the Panta II ankle nail remains on track.
Ankle sales overall grew in mid-single-digits, with good performance called out for the Cadence device. Shoulders grew in double digits. Extremities Ortho growth is expected to begin seeing more meaningful increases in 2H18.
Sources: Integra LifeSciences; ORTHOWORLD Inc. estimates
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
